Informace o publikaci
c-MET-mediated resistance to EGFR inhibitors in head and neck cancer: How to move from bench to bedside
| Autoři | |
|---|---|
| Rok publikování | 2016 |
| Druh | Článek v odborném periodiku |
| Časopis / Zdroj | Oral oncology |
| Fakulta / Pracoviště MU | |
| Citace | |
| www | http://www.sciencedirect.com/science/article/pii/S136883751630063X |
| Doi | http://dx.doi.org/10.1016/j.oraloncology.2016.05.017 |
| Obor | Onkologie a hematologie |
| Klíčová slova | squamous-cell carcinoma; randomized phase-ii; tivantinib arq 197; lung-cancer; acquired-resistance; metastatic head; plus erlotinib; double-blind; patients pts; placebo |
| Popis | Mesenchymal–epithelial transition factor (c-MET), found on melanocytes, endothelial cells, and epithelial tissues, is a membrane spanning receptor tyrosine kinase for hepatocyte growth factor (HGF), produced by elements of mesenchymal origin. The receptor-ligand pair controls diverse biological activities including cell proliferation, motility, invasiveness, morphogenesis, apoptosis, and angiogenesis. |